ArticleACS medicinal chemistry letters2017
Design and Synthesis of
Abstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Discovery of VU6066098: A Selective and CNS-Penetrant mGluACS chemical neuroscience · 2026Article
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing.Journal of pharmaceutical analysis · 2025Article
- Radiosynthesis and evaluation of anAmerican journal of nuclear medicine and molecular imaging · 2025Article
- Interactions between metabotropic glutamate and CB1 receptors: implications for mood, cognition, and synaptic signaling based on data from mGluR and CB1R-targeting drugs.Pharmacological reports : PR · 2024Review
- mGluPharmacology, biochemistry, and behavior · 2024Article
- mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.European archives of psychiatry and clinical neuroscience · 2023Review
- Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?Cellular and molecular neurobiology · 2023Review
- The role of thalamic group II mGlu receptors in health and disease.Neuronal signaling · 2022Review
- Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.Pharmacology, biochemistry, and behavior · 2022Review
- Advances in translating mGluPharmacology, biochemistry, and behavior · 2022Review
- The effects of predator odor (TMT) exposure and mGluNeuropharmacology · 2022Article
- Recent Advances of Pyridinone in Medicinal Chemistry.Frontiers in chemistry · 2022Review
- Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGluNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.Neuropharmacology · 2021Review
- Activating mGluBiological psychiatry · 2021Article
- Article
- mGluNeuron · 2020Article
- Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.Trends in pharmacological sciences · 2019Review
- Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Julie L EngersDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Katrina A BollingerVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Rebecca L WeinerVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Alice L RodriguezDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Madeline F LongVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Megan M BreinerVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Sichen ChangVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Sean R BollingerVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Michael BubserDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Carrie K JonesDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Ryan D MorrisonVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Thomas M BridgesDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Anna L BlobaumDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Kyle A EmmitteDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Funding
Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRELL, FRANK E. · 2015 to 2019
$7.1MDiscovery and Optimization of Selective Negative Allosteric Modulators of mGluR3R01MH099269 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2012 to 2014
$1.2MNICHD NIH HHS U54 HD083211NIMH NIH HHS R01 MH099269
Abstract
Herein, we detail the optimization of the mGlu
Indexed as
depressionmetabotropic glutamate receptor 3 (mGlu3)Negative allosteric modulator (NAM)physiochemical propertiesVU6010572
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.